MDGL - Madrigal Pharmaceuticals - Stock Forecast

Healthcare - Sector

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

MDGL is currently covered by 12 analysts with an average price target of $364.93. This is a potential upside of $86.7 (31.16%) from yesterday's end of day stock price of $278.23.

Madrigal Pharmaceuticals's activity chart (see below) currently has 142 price targets and 132 ratings on display. The stock rating distribution of MDGL is 86.36% BUY, 11.36% HOLD and 2.27% SELL.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 74.61% with an average time for these price targets to be met of 386.69 days.

Highest price target for MDGL is $460, Lowest price target is $392, average price target is $422.91.

Most recent stock forecast was given by MAYANK MAMTANI from B. RILEY on 02-May-2025. First documented stock forecast 29-Oct-2014.

Best performing analysts who are covering MDGL - Madrigal Pharmaceuticals:

Jonathan Wolleben Akash Tewari Yasmeen Rahimi Joel Beatty Joseph Pantginis Jay Olson Edward Nash Liisa Bayko Ed Arce Ritu Baral

Currently out of the existing stock ratings of MDGL, 38 are a BUY (86.36%), 5 are a HOLD (11.36%), 1 are a SELL (2.27%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Mayank Mamtani (B. RILEY)

Buy

$460

$184.74 (67.11%)

$422

1 months 4 days ago
(02-May-2025)

10/14 (71.43%)

$144.52 (45.81%)

261

Please subscribe to see the analyst performance score

Edward Nash (CANACCORD)

Buy

$420

$144.74 (52.58%)

$377

1 months 4 days ago
(02-May-2025)

11/13 (84.62%)

$104.52 (33.13%)

421

Please subscribe to see the analyst performance score

Jonathan Wolleben (JMP)

Buy

$443

$167.74 (60.94%)

$427

1 months 13 days ago
(24-Apr-2025)

5/13 (38.46%)

$123.07 (38.47%)

230

Please subscribe to see the analyst performance score

Ed Arce (HC WAINWRIGHT)

Buy

$405

$129.74 (47.13%)

$400

3 months 10 days ago
(27-Feb-2025)

14/18 (77.78%)

$49.12 (13.80%)

286

Please subscribe to see the analyst performance score

Liisa Bayko (EVERCORE)

Buy

$392

$116.74 (42.41%)

$360

4 months 24 days ago
(13-Jan-2025)

5/7 (71.43%)

$88.29 (29.07%)

308

Please subscribe to see the analyst performance score

Show more analysts

Load Price Targets and Ratings Chart

To gain access for the analyst/ stock price target chart please use a computer

What is MDGL (Madrigal Pharmaceuticals) average time for price targets to be met?

On average it took 386.69 days on average for the stock forecasts to be realized with a an average price target met ratio 74.61

Which analyst has the current highest performing score on MDGL (Madrigal Pharmaceuticals) with a proven track record?

JONATHAN WOLLEBEN

Which analyst has the most public recommendations on MDGL (Madrigal Pharmaceuticals)?

Jonathan Wolleben works at JMP and has 20 price targets and 12 ratings on MDGL

Which analyst is the currently most bullish on MDGL (Madrigal Pharmaceuticals)?

Andrea Tan with highest potential upside - $289.74

Which analyst is the currently most reserved on MDGL (Madrigal Pharmaceuticals)?

Matthew Luchini with lowest potential downside - -$164.26

Madrigal Pharmaceuticals in the News

Madrigal Pharmaceuticals, Inc. (MDGL): Among Nicholas J. Pritzker’s Stock Picks with Huge Upside Potential

We recently published an article titled Billionaire Nicholas J. Pritzker’s 8 Stocks with Huge Upside Potential.In this article, we are going to take a look at where Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) stands against Nicholas J. Pritzker’s other stock picks with huge upside potential. Nicholas J. Pritzker is the chairman and co-founder of Tao Capital Partners,...

Madrigal Pharmaceuticals Inc (MDGL) Q1 2025 Earnings Call Highlights: Strong Sales Growth and ...

Net Sales: $137.3 million in Q1 2025, up 33% from Q4 2024. Patient Growth: Over 17,000 patients on Rezdiffra by end of Q1 2025, up from 11,800 in Q4 2024. Prescriber Penetration: 70% of 6,000 top target prescribers have prescribed Rezdiffra. R&D Expenses: $44.2 million in Q1 2025, down from $71.2 million in Q1 2024....